secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2022-02-15T23:59:59+00:00
Accession:  0001104659-22-023796
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx posts Q4 revenue $3.7M (+75% YoY); FY2021 revenue $13.0M; guides FY2022 rev $20-23M
--------------------------------------------------------------------------------

- Q4 2021 revenue $3.7M, up 75% YoY; US HF revenue $2.7M, up 345%.
- Full year 2021 revenue $13.0M, up 115% YoY; net loss $43.1M ($4.16 per share).
- Guides FY2022 total revenue $20-23M; Q1 2022 revenue $3.6-4.0M; gross margin 74-76%.
- Received FDA approval for new IPG in Dec 2021; expects MRI labeling and new programmer approvals in H1 2022.
- Fully repaid $20M loan in Nov 2021; cash $142.1M at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922023796/0001104659-22-023796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922023796/tm226604d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-023796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer